Literature DB >> 18695159

SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia.

T Schmitz-Hübsch1, P Giunti, D A Stephenson, C Globas, L Baliko, F Saccà, C Mariotti, M Rakowicz, S Szymanski, J Infante, B P C van de Warrenburg, D Timmann, R Fancellu, R Rola, C Depondt, L Schöls, E Zdzienicka, J-S Kang, S Döhlinger, B Kremer, B Melegh, A Filla, T Klockgether.   

Abstract

OBJECTIVE: To evaluate the usefulness of functional measures in patients with spinocerebellar ataxia (SCA).
METHODS: We assessed three functional measures-8 m walking time (8MW), 9-hole peg test (9HPT), and PATA repetition rate-in 412 patients with autosomal dominant SCA (genotypes 1, 2, 3, and 6) in a multicenter trial.
RESULTS: While PATA rate was normally distributed (mean/median 21.7/20.5 per 10 s), the performance times for 8MW (mean/median 10.8/7.5 s) or 9HPT (mean/median 47.2/35.0 s in dominant, 52.2/37.9 s in nondominant hand) were markedly skewed. Possible learning effects were small and likely clinically irrelevant. A composite functional index (SCAFI) was formed after appropriate transformation of subtest results. The Z-scores of each subtest correlated well with the Scale for the Assessment and Rating of Ataxia (SARA), the Unified Huntington's disease Rating Scale functional assessment, and disease duration. Correlations for SCAFI with each of these parameters were stronger (Pearson r = -0.441 to -0.869) than for each subtest alone. Furthermore, SCAFI showed a linear decline over the whole range of disease severity, while 9HPT and 8MW had floor effects with respect to SARA. Analysis of possible confounders showed no effect of genotype or study site and only minor effects of age for 8MW.
CONCLUSION: The proposed functional measures and their composite SCAFI have favorable properties to assess patients with spinocerebellar ataxia.

Entities:  

Mesh:

Year:  2008        PMID: 18695159     DOI: 10.1212/01.wnl.0000324863.76290.19

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  47 in total

Review 1.  Emerging therapies in Friedreich's ataxia.

Authors:  Tanya V Aranca; Tracy M Jones; Jessica D Shaw; Joseph S Staffetti; Tetsuo Ashizawa; Sheng-Han Kuo; Brent L Fogel; George R Wilmot; Susan L Perlman; Chiadi U Onyike; Sarah H Ying; Theresa A Zesiewicz
Journal:  Neurodegener Dis Manag       Date:  2016

2.  Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia.

Authors:  I Giordano; M Bogdanow; H Jacobi; K Jahn; M Minnerop; L Schoels; M Synofzik; J Teufel; T Klockgether
Journal:  J Neurol       Date:  2013-07-04       Impact factor: 4.849

Review 3.  Consensus Paper: Neurophysiological Assessments of Ataxias in Daily Practice.

Authors:  W Ilg; M Branscheidt; A Butala; P Celnik; L de Paola; F B Horak; L Schöls; H A G Teive; A P Vogel; D S Zee; D Timmann
Journal:  Cerebellum       Date:  2018-10       Impact factor: 3.847

4.  Application of Quantitative Motor Assessments in Friedreich Ataxia and Evaluation of Their Relation to Clinical Measures.

Authors:  Christian Hohenfeld; Imis Dogan; Robin Schubert; Claire Didszun; Ludger Schöls; Matthis Synofzik; Ilaria A Giordano; Thomas Klockgether; Jörg B Schulz; Ralf Reilmann; Kathrin Reetz
Journal:  Cerebellum       Date:  2019-10       Impact factor: 3.847

Review 5.  Spinocerebellar ataxias: prospects and challenges for therapy development.

Authors:  Tetsuo Ashizawa; Gülin Öz; Henry L Paulson
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

6.  A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2.

Authors:  Francesco Saccà; Giorgia Puorro; Arturo Brunetti; Giovambattista Capasso; Amedeo Cervo; Sirio Cocozza; Mariafulvia de Leva; Angela Marsili; Chiara Pane; Mario Quarantelli; Cinzia Valeria Russo; Francesco Trepiccione; Giuseppe De Michele; Alessandro Filla; Vincenzo Brescia Morra
Journal:  J Neurol       Date:  2014-10-28       Impact factor: 4.849

7.  Cytokines in Machado Joseph Disease/Spinocerebellar Ataxia 3.

Authors:  Gerson da Silva Carvalho; Jonas Alex Morales Saute; Clarissa Branco Haas; Vitor Rocco Torrez; Andressa Wigner Brochier; Gabriele Nunes Souza; Gabriel Vasata Furtado; Tailise Gheno; Aline Russo; Thais Lampert Monte; Artur Schumacher-Schuh; Rui D'Avila; Karina Carvalho Donis; Raphael Machado Castilhos; Diogo Onofre Souza; Maria Luiza Saraiva-Pereira; Vanessa Leotti Torman; Suzi Camey; Luis Valmor Portela; Laura Bannach Jardim
Journal:  Cerebellum       Date:  2016-08       Impact factor: 3.847

8.  Inventory of Non-Ataxia Signs (INAS): validation of a new clinical assessment instrument.

Authors:  H Jacobi; M Rakowicz; R Rola; R Fancellu; C Mariotti; P Charles; A Dürr; M Küper; D Timmann; C Linnemann; L Schöls; O Kaut; C Schaub; A Filla; L Baliko; B Melegh; J-S Kang; P Giunti; B P C van de Warrenburg; R Fimmers; T Klockgether
Journal:  Cerebellum       Date:  2013-06       Impact factor: 3.847

9.  Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3.

Authors:  Mercedes Prudencio; Hector Garcia-Moreno; Karen R Jansen-West; Rana Hanna Al-Shaikh; Tania F Gendron; Michael G Heckman; Matthew R Spiegel; Yari Carlomagno; Lillian M Daughrity; Yuping Song; Judith A Dunmore; Natalie Byron; Björn Oskarsson; Katharine A Nicholson; Nathan P Staff; Sorina Gorcenco; Andreas Puschmann; João Lemos; Cristina Januário; Mark S LeDoux; Joseph H Friedman; James Polke; Robin Labrum; Vikram Shakkottai; Hayley S McLoughlin; Henry L Paulson; Takuya Konno; Osamu Onodera; Takeshi Ikeuchi; Mari Tada; Akiyoshi Kakita; John D Fryer; Christin Karremo; Inês Gomes; John N Caviness; Mark R Pittelkow; Jan Aasly; Ronald F Pfeiffer; Venka Veerappan; Eric R Eggenberger; William D Freeman; Josephine F Huang; Ryan J Uitti; Klaas J Wierenga; Iris V Marin Collazo; Philip W Tipton; Jay A van Gerpen; Marka van Blitterswijk; Guojun Bu; Zbigniew K Wszolek; Paola Giunti; Leonard Petrucelli
Journal:  Sci Transl Med       Date:  2020-10-21       Impact factor: 17.956

10.  A randomized pilot study of stochastic vibration therapy in spinocerebellar ataxia.

Authors:  O Kaut; H Jacobi; C Coch; A Prochnicki; M Minnerop; T Klockgether; U Wüllner
Journal:  Cerebellum       Date:  2014-04       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.